Behavioral effects of protirelin in schizophrenia

Area of Science:

• Psychiatry
• Neuroendocrinology

Background:

• Chronic schizophrenia is a complex mental disorder often treated with neuroleptics.
• Adjunctive therapies are explored to enhance treatment efficacy and manage residual symptoms.

Purpose of the Study:

• To evaluate the efficacy and safety of protirelin as an add-on therapy for chronic schizophrenia.
• To assess the impact of protirelin on specific symptom domains and overall patient functioning.

Main Methods:

• A multi-institutional, double-blind, placebo-controlled study involving 143 chronic schizophrenic patients.
• Patients received standard neuroleptic treatment plus either 4 mg oral protirelin daily or placebo for 14 days.

Main Results:

• Protirelin demonstrated statistically significant superiority over placebo in physicians' global efficacy ratings.
• Improvements were noted in motivation, facial expression, emotional rapport, and psychomotor activity.
• Therapeutic effects typically emerged within one week of protirelin administration.

Conclusions:

• Protirelin is a safe and effective adjunctive treatment for chronic schizophrenia.
• It offers potential benefits for improving motivation and other negative symptoms in schizophrenic patients.
• The rapid onset of action suggests a promising therapeutic profile for protirelin.